Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease

Annals of Neurology

Volumn 44, Issue 3, 1998, Pages 410-413

  Montine, T J ^a,b   Markesbery, W R ^c   Morrow, J D ^a,b   Roberts II, L J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; LATERAL BRAIN VENTRICLE; LIPID OXIDATION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; CEREBROSPINAL FLUID;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DINOPROST; FEMALE; HUMANS; MALE;

EID: 0031594916     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440322     Document Type: Article

References (14)

1. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147
2. Lovell M, Ehmann W, Mattson M, Markesbery W. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997;18:457-461
3. Montine TJ, Montine KS, Swift LL. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 1997;151: 1571-1575
4. Morrow J, Hill K, Burk R, et al. A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-9387
5. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997;36:1-21
6. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472
7. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105
8. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
9. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259
10. Roberts L, Morrow J. Formation of novel isoprostane-like compounds from docosahexaenoic acid. In: Isma RA, Armstrong RA, Kelly RW, Wilson R, eds. Fourth international congress on essential fatty acids and eicosanoids, 1997. Champaign, IL: American Oil Chemists' Society (In press)
11. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630
12. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:4725-4727
13. Ahlskog J, Utti R, Low P, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995;10:566-573
14. Kuksis A. Fatty acid composition of glycerolipids of animal tissues. Kuksis A, ed. Handbook of lipid research. New York: Plenum Press, 1978:381-442